In patients with HoFH, ANGPTL3 inhibitors can lead to a nearly 50% reduction in LDL-C [77], offering hope for FH patients and improving lipid-lowering options for individuals with high residual cardiovascular risk or statin intolerance. This evidence concerns the gene ANGPTL3 and familial hyperaldosteronism.